Tehran University of Medical Sciences Basic & Clinical Cancer Research 2228-6527 8 4 2017 02 25 29 36 EN Mehrnoosh Pashaei Cancer Research Center and Department of Immunology, Semnan University of Medical Sciences,Semnan, Iran. Mahdieh Shokrollahi Cancer Research Center and Department of Immunology, Semnan University of Medical Sciences, Semnan, Iran. AND Immunology, Asthma and AllergyResearch Center, Tehran Universityof Medical Sciences, Tehran, Iran. Parviz Kokhaei Department of immunology, Semnan University of Medical Sciences, Semnan, Iran. AND Immune Gene therapy Lab Department of Oncology-Pathology,Immune and Gene therapy Lab,Cancer Center Karolinska , Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden. 2016 11 21 2017 01 10 Chronic lymphocyte leukemia (CLL) is the most common leukemia in elderly individuals that is accompanied by the presence of CD5/CD19/CD20/CD23 positive, FMC7 negative and reduced levels of surface membrane Immunoglobuline (IgM & IgD), CD79b on B lymphocytes in the blood, bone marrow and lymph nodes. Remarkably, based on the mutational IgVH status, B-CLL cases can be subdivided into two prognostic groups: the first one with presence mutation (≥ 2%) in VH gene and second one with absence mutation (≤ 2%) in VH gene that is the mutation of IgVH status, affected on progression and overall survival of CLL patients. Correspondingly, also the expression level of several markers is correlated with the mutation of IgVH status and prognosis of CLL disease. In this review we focused on relation between mutation IgVH status and CLL prognosis and overall survival and also some cellular markers which may affect CLL clinical status. https://bccr.tums.ac.ir/index.php/bccrj/article/view/218 https://bccr.tums.ac.ir/index.php/bccrj/article/download/218/02